Pipeline

We employ biologic and small molecule-based approaches that are designed to enhance the ability of the patient’s own immune system to detect and destroy cancer cells. Our clinical programs, TTI-621 and TTI-622, are immune checkpoint inhibitors targeting CD47. We have a discovery-stage small molecule STING agonist program, and an early-stage undisclosed CD47 program.

Target

CD47 – Innate Immune Checkpoint

Indication

T-cell lymphoma, solid cancers

DiscoveryPreclinicalPhase 1aPhase 1b/2

Candidate

TTI-621 (Intravenous)

Indication

B- and T-cell lymphomas, other blood cancers

DiscoveryPreclinicalPhase 1aPhase 1b/2

Candidate

TTI-622

Indication

Lymphoma, myeloma

DiscoveryPreclinicalPhase 1aPhase 1b/2

Indication

Cancer

DiscoveryPreclinicalPhase 1aPhase 1b/2